Lonapegsomatropin

From WikiProjectMed
Jump to navigation Jump to search

Lonapegsomatropin
Names
Trade namesSkytrofa
Other namesLonapegsomatropin-tcgd; Lonapegsomatropin Ascendis Pharma; rhGH-PEG; ACP-011; ΤransConPEG hGh; WHO-10598
Clinical data
Drug classGrowth hormone receptor agonist
Main usesGrowth hormone deficiency[1]
Side effectsHeadache, joint pain, low thyroid, pain at the site of injection[2]
Routes of
use		Subcutaneous injection
Legal
License data
Legal status
Chemical and physical data
FormulaC1051H1627N269O317S9[C2H4O]4n

Lonapegsomatropin, sold under the brand name Skytrofa, is a medication used to treat growth hormone deficiency.[1] It may be used in children from the ages of 1 to 18 year.[1][2] It is given by injection under the skin once per week.[2]

Common side effects include headache, joint pain, low thyroid, and pain at the site of injection.[2] Other side effects may include allergic reactions, cancer, diabetes, intracranial hypertension, swelling, pancreatitis, and slipped capital femoral epiphysis.[1] It is a human growth hormone (somatropin) that has been developed to be long acting.[1][2]

Lonapegsomatropin was approved for medical use in the United States in 2021 and Europe in 2022.[1][2] In the United States it costs 2,800 to 12,300 USD per week, depending on the weight of the child.[4] As of 2022 it is not yet commercial available in Europe.[5]

Medical uses

Lonapegsomatropin is a growth hormone therapy indicated to treat growth hormone deficiency.[1][2] It is equivalent to somatropin but only needs to be given once per week.[2]

Dosage

The typical dose is 0.24 mg/kg by injection once per week.[1]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 "Skytrofa- lonapegsomatropin-tcgd injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 1 October 2021. Retrieved 30 September 2021.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 "Lonapegsomatropin Ascendis Pharma EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 16 March 2022. Retrieved 16 March 2022.
  3. ↑ "Skytrofa: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 26 August 2021. Retrieved 25 August 2021.
  4. ↑ "Skytrofa Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved 27 October 2022.
  5. ↑ "Lonapegsomatropin". SPS - Specialist Pharmacy Service. 7 March 2019. Archived from the original on 17 January 2022. Retrieved 27 October 2022.

Further reading

External links

External sites:
Identifiers:
  • Clinical trial number NCT02781727 for "A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)" at ClinicalTrials.gov
Stub icon

This hormonal preparation article is a stub. You can help MDWiki by expanding it.

Retrieved from "https://mdwiki.org/w/index.php?title=Lonapegsomatropin&oldid=1379365"